We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Prostate Cancer Severity Indicated by Location and Concentration of Syntaphilin

By LabMedica International staff writers
Posted on 20 May 2019
A biomarker has been identified that may enable doctors to predict which patients with early indications of prostate cancer will be likely to develop the much more serious invasive and metastatic form of the disease.

About 10% of prostate cancer patients develop locally invasive and metastatic disease, with increased severity, limited treatment options, and the likelihood of death. More...
For these individuals, easily accessible biomarkers that may inform on the metastatic potential of localized prostate cancer are urgently needed.

Investigators at Yale University (New London, CT, USA) are among those searching for such biomarkers. In this regard, they showed that syntaphilin (SNPH), a molecule originally identified as a negative regulator of mitochondrial dynamics in neurons, was abundantly expressed in prostate cancer. SNPH distribution in prostate cancer was found to be spatially biphasic, with high expression at the invasive front, correlating with increased proliferative rates, and reduced levels in the central tumor bulk, which were further decreased in patients with distant metastases.

Higher levels of SNPH were observed with increasing Gleason grade. The majority of treatable cancers are of Gleason scores five to seven, while tumors with Gleason scores eight to 10 tend to be advanced neoplasms that are unlikely to be cured.

The investigators also found that prostate tumors predominantly expressed a novel, extraneuronal isoform of SNPH that accumulated in mitochondria and maintained oxidative metabolism and tumor cell proliferation. Therefore, they speculated that SNPH could be a novel marker of high Gleason grade prostate cancer, differentially expressed at the invasive front compared with the central tumor bulk, and was potentially down regulated in the metastatic form of the disease.

"Predicting aggressive behavior in prostate cancer is an entirely unmet and urgent need. There are currently no tissue-based biomarkers to help clinicians reliably identify the subset of prostate cancer patients who will progress to life-threatening, disseminated disease and who would, therefore, benefit from systemic therapies before or following prostatectomy. If our findings are supported by larger studies, SNPH measurement in tumors could be developed into a predictive biomarker," said senior author Dr. Marie E. Robert, professor of pathology at Yale University. "This is the first study to suggest a clinical role for SNPH assessment in prostate cancer prognosis, potentially confirming recent evidence in experimental models of its importance in the phenotypic switch between proliferative and metastatic tumor states. Our results also reaffirm a critical, emerging role of mitochondrial biology in influencing tumor behavior."

The syntaphilin study was published in the May 9, 2019, online edition of The American Journal of Pathology.

Related Links:
Yale University


New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
New
Automated PCR Setup
ESTREAM
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.